Synovus price target lowered to $55 from $56 at Truist

Truist lowered the firm’s price target on Synovus (SNV) to $55 from $56 and keeps a Buy rating on the shares as part of a broader research note on Regional Banks, updating the firm’s models following their Q3 results. The firm is raising its estimates on higher revenue but revising its price target down pending the Pinnacle-Synovus deal closing in early 2026, the analyst tells investors in a research note.